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Fig. 1. CT showed a mass (54×28 mm) with dif-
fuse enhancement flaring ribs and invasion
to muscles (arrow).
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A case of renal cell carcinoma presenting with paraneoplastic syndrome is reported. A 69-year-old
man with uncontrolled diabetes was incidentally found to have a left thoracic tumor and a right renal tumor.
He had intermittent fever of 39°C or more and laboratory data showed diabetes and high C-reactive protein
level. A radical nephrectomy was performed, but the neoplastic syndrome did not improve. After a
second surgery consisting of complete resection of solitary bone metastasis the symptoms resolved
immediately. At 6 months postoperatively, he had no reccurence. Generally prognosis of patients with
bone metastasis from renal cell carcinoma has been said to be poor, but surgical control of bone metastasis
may be a key factor for the prognosis of patient with metastatic RCC in the era of targeted therapy.
(Hinyokika Kiyo 60 : 171-174, 2014)







患 者 : 69歳，男性
主 訴 : 発熱，血糖コントロール不良
既往歴 : 脂質異常症，糖尿病（食事療法）





入院時現症 : 体温 38.9°C，間欠熱，血圧 120/76，
脈拍 120/分，整，左胸壁乳頭皮下に手拳大の腫瘤性
病変あり，胸壁固定あり，皮膚固定なし，体表リンパ
節触知せず，身長 163 cm，体重 51 kg， 1カ月で 4 kg
の体重減少あり，Karnofsky Performance Status 80％．
入院時検査所見 :
血液生化学 : WBC 8, 600/ μ l，Hb 9. 2 g/dl，Plt
31.8×104，補正 Ca 10.3 mg/dl，LDH 165 U/l，AST
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Fig. 2. CT showed a mass (36 × 32 mm) with






Fig. 3. (A) Macroscopic appearance of resected
specimen of the right kidney. The cut
surface of the tumor was yellow and solid
(arrow). (B) Microscopic appearance of the
resected specimen of the right kidney





Fig. 4. (A) The macroscopic appearance of resected
specimen of the left chest wall. a : tumor,
b : ribs, c : skin, d : greater pectoral muscle.
(B) The microscopic appearance of resected
specimen of the left chest wall revealed 4th
rib metastasis from renal cell carcinoma.
26 U/l，ALT 28 U/l，ALP 885 U/l，γGTP 133 U/l，
T-Bil 0. 7 mg/dl，CRP 25. 7 mg/dl，Glu 357 mg/dl，
HbA1c (NGSP) 11.1％．
尿検査 : 尿蛋白定性 2＋，尿糖定性 3＋．
















病理組織所見○1 : Renal cell carcinoma，clear cell
carcinoma，3. 4 × 2. 8 mm，G2 ＞ 1 ＞ 3，pT1a，ly
(−)，v (−)，INFβ (Fig. 3B）．
術後経過○1 : 37∼39°C 台の発熱が持続し，血糖値
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Fig. 5. Transitional changes of WBC, CRP, blood glucose, HbA1c and maximum temperature. After the
second operation, an immediate decrease in CRP, blood glucose and temperature occurred, the patient
required no further insulin therapy. Day 0 is the day of initial visit to our hospital.
200 mg/dl 前後，血清 CRP 値も20台で推移した．CT














病理組織所見○2 : Clear cell carcinoma，G2，7×6
cm，壁側胸膜浸潤なし，筋浸潤あり，断端陰性 (Fig.
4B）．





























巣，転移巣ともに G2 と変わらず，IL-6 や CRP など
の特殊免疫染色は施行していないため推測の域を出な
い．
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